Last reviewed · How we verify
AGN-210669 ophthalmic solution, 0.1%
AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.
AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye. Used for Treatment of noninfectious uveitis affecting the posterior segment of the eye.
At a glance
| Generic name | AGN-210669 ophthalmic solution, 0.1% |
|---|---|
| Sponsor | Allergan |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Corticosteroids like AGN-210669 work by inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes, which contribute to the inflammatory response. This leads to a reduction in swelling, redness, and pain in the affected area. AGN-210669 is administered topically to the eye to minimize systemic side effects.
Approved indications
- Treatment of noninfectious uveitis affecting the posterior segment of the eye
Common side effects
- Increased intraocular pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-210669 ophthalmic solution, 0.1% CI brief — competitive landscape report
- AGN-210669 ophthalmic solution, 0.1% updates RSS · CI watch RSS
- Allergan portfolio CI